About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
ACOR - Acorda Therapeutics| Previous Close | $6.19 | Open | |
| Volume | Market Cap | 56.43M | |
| Yield | Last Dividend |
| Acorda Fourth Quarter/Year End 2020 Upda... | 02/25/21 |
| ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021 | |
| Acorda Therapeutics Announces Completion... | 02/11/21 |
| ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent | |
| FXNEWS24 |Acorda (ACOR) to Report This a... | 02/08/21 |
| Acorda (ACOR) to Report This autumn Earnings: What's within the Playing cards? | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex ... | |
| Acorda Stock at $35 a Share? This Analys... | 01/15/21 |
| It's been a stellar week for Acorda Therapeutics (ACOR) investors. The stock skyrocketed over 60% after the company announced it is selling its manufa... | |
| After the latest announcements 44.34% sh... | 01/14/21 |
| Yesterday, Acorda Therapeutics made several announcements which triggered the stock price to rise a week after its stock split. | |
| The Daily Biotech Pulse: Bausch Health I... | 01/13/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12) Abb... | |
| Acorda Therapeutics Announces Agreement ... | 01/13/21 |
| ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into a definitive agreement to sell its I... | |
| Global Longevity and Anti-Senescence The... | 01/13/21 |
| InsightAce Analytic Pvt. Ltd. features the release of market research report on ???Global Longevity and Anti-Senescence Therapy Market Assessment ??? ... | |
| Acorda Therapeutics to Present at 39th A... | 01/12/21 |
| ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will p... | |
| Acorda Therapeutics to Present at H.C. W... | 01/11/21 |
| Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present during the January 11th -1... | |
| Preliminary complaint of Association of ... | 01/04/21 |
| The Association of Romanian Communes (ACoR) has submitted a preliminary complaint with the Government, the ministries of Finance, Labour, Development ... | |
| Acorda Therapeutics Announces Completion... | 12/31/20 |
| ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the previously announced 1-for-6 revers... | |
| Cerebral Palsy Market Global Key players... | 12/15/20 |
| Market Scenario Cerebral palsy (CP) is a group of lifelong neurological disorders that affect movement and coordination, caused by damage to or abnorm... | |
| Orphan Drugs Market Demand Increased - A... | 12/09/20 |
| Global Orphan Drugs Market: The report provides a valuable source of insightful data for business strategists and competitive analysis of Orphan Drugs... | |
| Primary Sclerosing Cholangitis Market To... | 11/06/20 |
| Primary Sclerosing Cholangitis Market research report is formulated with the exact understanding of customer requirements. Market status at the global... | |
| Acorda Reports Third Quarter 2020 Financ... | 11/03/20 |
| ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ:ACOR) today reported its financial results for the third quarter ended September 30,... | |
| Acorda Therapeutics Earnings Report: Her... | 11/03/20 |
| Acorda Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by??? | |
| Acorda Third Quarter 2020 Update: Webcas... | 10/27/20 |
| ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its third quarter... | |
| Acorda Therapeutics (NASDAQ:ACOR) Rating... | 10/25/20 |
| Zacks Investment Research lowered shares of Acorda Therapeutics (NASDAQ:ACOR) from a hold rating to a sell rating in a research note published on Wedn... | |
| Acorda Therapeutics (NASDAQ:ACOR) Cut to... | 10/24/20 |
| Zacks Investment Research lowered shares of Acorda Therapeutics (NASDAQ:ACOR) from a hold rating to a sell rating in a research report released on Wed... | |
| Acorda Therapeutics (NASDAQ:ACOR) Tradin... | 10/24/20 |
| Acorda Therapeutics, Inc. (NASDAQ:ACOR)???s share price fell 7% on Thursday . The company traded as low as $0.77 and last traded at $0.87. 5,770,156 s... | |
| Zacks Investment Research Lowers Acorda ... | 10/24/20 |
| Zacks Investment Research cut shares of Acorda Therapeutics (NASDAQ:ACOR) from a hold rating to a sell rating in a report released on Wednesday, Zacks... | |
| Wedbush Brokers Raise Earnings Estimates... | 10/23/20 |
| Acorda Therapeutics, Inc. (NASDAQ:ACOR) ??? Stock analysts at Wedbush boosted their Q3 2020 EPS estimates for Acorda Therapeutics in a research note i... | |
| Acorda Therapeutics (NASDAQ:ACOR) Stock ... | 10/22/20 |
| Acorda Therapeutics (NASDAQ:ACOR) was downgraded by Zacks Investment Research from a ???hold??? rating to a ???sell??? rating in a research report iss... | |
| Acorda Therapeutics (NASDAQ:ACOR) Shares... | 10/22/20 |
| Acorda Therapeutics, Inc. (NASDAQ:ACOR) fell 7% on Thursday . The company traded as low as $0.77 and last traded at $0.87. 5,770,156 shares traded han... | |
| Acorda Therapeutics Target of Unusually ... | 10/22/20 |
| Acorda Therapeutics, Inc. (NASDAQ:ACOR) was the recipient of unusually large options trading on Tuesday. Stock investors purchased 3,794 call options ... | |
| Q3 2020 Earnings Estimate for Acorda The... | 10/21/20 |
| Acorda Therapeutics, Inc. (NASDAQ:ACOR) ??? Equities research analysts at Wedbush upped their Q3 2020 EPS estimates for Acorda Therapeutics in a resea... | |
| Acorda Therapeutics (NASDAQ:ACOR) Downgr... | 10/21/20 |
| Acorda Therapeutics (NASDAQ:ACOR) was downgraded by Zacks Investment Research from a ???hold??? rating to a ???sell??? rating in a research note issue... | |
| Zacks Investment Research Downgrades Aco... | 10/21/20 |
| Acorda Therapeutics (NASDAQ:ACOR) was downgraded by Zacks Investment Research from a ???hold??? rating to a ???sell??? rating in a research note issue... | |
| Acorda Therapeutics, Inc. (NASDAQ:ACOR) ... | 10/20/20 |
| Acorda Therapeutics, Inc. (NASDAQ:ACOR) saw a large increase in short interest during the month of September. As of September 30th, there was short in... | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Big Data Zhou | Zhou Academy | 82.00 % | Subscribe |
| LavaPit | Steve Pitkin | 57.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
